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Abstract 
A previous commentary in INNOVATIONS in Pharmacy argued that, given the lack of evidence for outcomes in medical marijuana, 
outside of a handful of randomized clinical trials and even fewer observational studies, good clinical practice points to the need for 
monitoring patients who received cannabis through certified medical marijuana dispensaries. The commentary noted the lack of 
standards for monitoring cannabis patients and the lack of feedback from the dispensary to providers. Botanical cannabis 
administration was occurring in, effectively, an evidence vacuum. More to the point, dispensary owners and investors seem 
uninterested in establishing a robust evidence base for cannabis outcomes.  Given the range of conditions and symptoms presented by 
patients, to include the prevalence of multiple symptoms together with the range of potential cannabis formulations, dosing regimens 
and delivery options, a failure to monitor patients over the course of their exposure to cannabis in not acceptable. The purpose of this 
commentary is to report on a proposed on-line registry structure proposed by Prometheus Research for medical marijuana dispensaries 
in the US. The registry tracks and reports on patients over the course of treatment with botanical cannabis with the focus on severe or 
chronic non-cancer pain, severe nausea, persistent muscle spasms and seizures, together with prevalent comorbidities – fatigue, 
anxiety, depression and sleep. This is the first time a registry has been developed for dispensaries in the United States as a model for a 
robust evidence base to support botanical cannabis as a therapy option. 
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Introduction 
In a previous commentary in INNOVATIONS in Pharmacy the 
issue was raised as to the apparent lack of interest by state 
governments in legislating for monitoring standards for 
botanical marijuana or cannabis use by medical marijuana 
dispensaries 1. The commentary noted the lack of standards for 
monitoring cannabis patients and the lack of feedback from the 
dispensary to providers. A second commentary  considered the 
standards that should be expected from a cannabis registry in 
order both to address the issue of patient risk management and 
to establish credibility for outcomes claims 2.  As the 
commentaries emphasized, botanical cannabis administration 
is occurring in, effectively, an evidence vacuum. To date, the 
emphasis has been on licensing and regulating dispensaries, 
establishing standards for the presence of clinical pharmacists, 
physicians or other medical professionals at the point of sale 
with minimum reporting requirements. The result is that while 
access to cannabis through dispensaries is controlled, with 
patient certification limited to certain disease states and 
conditions or symptoms reported, dispensary managers, 
investors in dispensaries, state governments and providers, 
have little if any idea as to whether or not the provision of 
various cannabis formulations and delivery options have a 
clinically significant impact. Whether investors and managers 
would have an interest is a moot point. After all, establishing a  
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registry may be seen as an unnecessary impost if the primary 
interest is cannabis sales (with a tax base for state 
governments).  
 
Unfortunately, the situation is made worse by the absence of 
high quality data, either from randomized clinical trials (RCTs) 
and observational studies, for the conditions typically 
presented at dispensaries: severe non-cancer pain, severe 
nausea and persistent muscle spasms, PTSD. If we are 
concerned (and dispensaries may not be) with the place of 
botanical cannabis in therapy for these and other conditions 
then a commitment to a process and duty of care should be 
accepted by both dispensary management and legislative 
authorities. 
 
The purpose of this commentary is to report on a proposed 
dispensary registry by Prometheus Research (New Haven, CT). 
The registry is designed in a modular form to track conditions 
selected by the dispensary with a range of reporting options for 
providers, dispensary management and state marijuana 
agencies. A primary focus in the registry is on monitoring and 
reporting outcomes for severe pain. This is the key patient 
group for dispensaries, accounting for some 80% of conditions 
reported and, by extension, driving some 80% of dispensary 
revenue. A failure to accommodate the range of conditions 
reported as severe pain, to include both neuropathic pain and 
the body locations reported for pain intensity and functional 
status under the umbrella nociceptive pain is a major barrier to 
the acceptance of botanical cannabis.  
From a revenue perspective a failure to monitor and report 
outcomes creates an unnecessary barrier to a wider acceptance 
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of cannabis in pain management, with dispensaries as 
necessary intermediaries. Rather than an unnecessary impost, 
the argument to be made is that for a dispensary to be 
considered as an integral part of a process and duty of care, it 
needs to meet standards for reporting outcomes that allow it 
to contribute not only to a needed evidence but to provide a 
basis for the development of condition specific guidelines for 
botanical cannabis. 
Cannabis Registry Overview 
Registries are an accepted and widely utilized vehicle for 
monitoring outcomes, evaluating claims, quality improvement 
and informing value-based payment models. Of particular 
importance is the use of registries to generate a structured data 
set for patient-centered outcomes research following guidance 
standards proposed by the Patient Centered Outcomes 
research Institute (PCORI) 3 . The recommended minimum 
standards proposed by PCORI (17 in all) are addressed in the 
design of the cannabis registry proposed here. The key 
recommendations include:  
 
• Data analysis, collection and reporting standards 
• Choice of clinically meaningful outcomes 
• Adoption of validated scales for conditions treated 
• Inclusion of a quality assurance plan for data review 
and verification 
• Consistency in data collection 
• Ability to address potential confounding issues 
 
As well as meeting the PCORI standards, there are other aspects 
of the proposed Prometheus registry that should be 
emphasized in its design and data capture:  
 
• conditions and symptoms presented 
• medication utilization  
• opioid utilization and sparing 
• choice of validated patient reported outcomes (PRO) 
instruments for conditions and co-morbidities 
• cannabis administration options 
• cannabis dosing and titration 
• provider interaction  
• claims interpretation 
• provider benefits   
 
Conditions and Symptoms 
Conditions presented at dispensaries are dominated by severe 
pain. In Colorado, for example, severe pain accounts for 94% of 
conditions reported (July 2018) 4. Muscle spasms are the 
second most frequently reported condition (31%) with severe 
nausea accounting for 14% in Colorado). Seizures are reported 
with a low frequency (3%).  
 
A range of other conditions are reported ranging from PTSD 
(Colorado 7%) to glaucoma and HIV/AIDS. These conditions are 
not captured at the moment with the Prometheus registry with 
condition specific validated instruments either because of the 
difficulty of applying patient reported outcomes (e.g., PTSD) or 
the low frequency of potential respondents. These can, of 
course, always be captured as the registry develops.  
 
Not all patients report with a single condition. In Colorado 
88,143 (July 2018) patients reported 137,382 conditions or a 
ratio of 1.56 conditions per patient. The possibility of patients 
presenting with multiple conditions is accommodated within 
the registry design (detailed below).  
 
Information Flows 
The proposed registry design monitors patients through online 
reporting to sets of structured questions in real time. These 
responses capture the major conditions and symptoms, 
providing feedback to both dispensary management and the 
patient’s provider on response to therapy. Responses are 
cumulative, collected at each dispensary visit with online input 
from clinical staff complementing patient responses. Response 
to specific cannabis formulations is captured through validated 
scales. The primary focus is on severe pain, but with the ability 
to monitor and report outcomes for severe nausea, muscle 
spasms and cramps and seizures. Following baseline 
assessment at initial visit, the registry outcomes capture: 
 
• Severe pain: reduction in overall pain intensity and 
improvement in (i) location specific pain intensity and 
functionality scores and (ii) neuropathic pain 
• Persistent Muscle Spasms: reduction in frequency, 
severity and timing of spasms and cramps  
• Severe nausea (chemotherapy): reduction in 
frequency and severity of nausea and vomiting prior 
to, during and following a chemotherapy episode 
• Severe nausea (other): reduction in frequency and 
severity of nausea and vomiting 
• Seizures (epilepsy): assessment of potential 
improvement in the quality of life    
 
When patients present with multiple conditions, the proposed 
registry design accommodates responses for two conditions 
capturing any two combinations of severe pain, severe muscle 
spasms, severe nausea and seizures. Where other 
combinations are presented the patient only responds to the 
specific questions for one of the four conditions. If for example 
the conditions are severe pain and severe nausea (other) then 
the on-line data input will accommodate both responses and 
monitor these over time. If, again for example, the patient 
reports severe pain and PTSD, the patient will only respond to 
questions for severe pain. The registry will, of course, list all 
conditions reported. 
 
Validated Instruments 
A registry offers the opportunity to define and standardize 
response to therapy over baseline through the adoption of 
validated patient reported outcome (PRO) instruments. Two 
types of instrument are included: (i) PRO instruments, where 
available, that are specific to the symptom or condition being 
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treated and (ii) PRO instruments that are more general in 
capturing high prevalence co-morbidities for the conditions 
being treated. The former PRO instruments would include, as 
detailed below, a range of scales for pain intensity and 
functional status for patients receiving cannabis for severe pain. 
As this is the most common condition reported, particular 
attention is given to developing a suite of validated PRO 
instruments to monitor nociceptive pain status by body 
location as well as for neuropathic pain. In the latter case the 
PRO instruments proposed are for common co-morbidities 
which may not be classified as a treatable condition but which 
are appropriate in evaluating status change: fatigue, anxiety, 
depression and sleep experience. It is recognized that condition 
specific PRO instruments can also address these conditions as 
single items or as sub-scales. This possible duplication should 
be traded off against including a validated instrument (e.g., the 
PHQ-9 for depression) which is widely accepted, with known 
properties and has reference points for evaluating clinically 
important differences in therapy response 5.  
 
In respect of severe pain, the outcomes covered by the 
proposed registry  are also consistent with those proposed as 
core outcomes for chronic pain clinical trials by the Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT) 6. The six core IMMPACT domains are outcomes 
representing: (i) pain, (ii) physical functioning; (iii) emotional 
functioning; (iv) participant ratings of improvement and 
satisfaction with treatment; (v) symptoms and adverse events; 
and (vi) participant disposition (e.g., persistence/adherence).  
 
At the same time it is important to capture, alongside the PRO 
instrument,  measures of change in the patient’s perception of 
the impact of cannabis. In the proposed registry, they are asked 
to respond to the Patients Global Improvement Scale (PGIC) at 
each subsequent dispensary visit 7. The PGIC is the patient 
reported outcome counterpart to the Clinical Global Impression 
(CGI) scale, consisting of one item taken from the scale and 
adapted to the patient. It is used widely in pivotal RCTs and is 
intended to generate the overall perception by the patient of 
the impact of the therapy received, if any, on activity 
limitations, symptoms, emotions and overall quality of life since 
beginning treatment. The response is on a 7-point scale from 
‘no change (or condition has got worse’ to ‘a great deal better 
and a considerable improvement that has made all the 
difference’. Patients also respond on a Likert scale on the 
degree of change from ‘much better’ to ‘much worse’. The PGIC 
is important because it captures the patient’s overall belief 
rather than, in the case of severe pain for example, responses 
in terms of pain intensity and functional status. The two 
responses may not correlate.    
 
Medication Utilization and Opioids 
Given the fact that the single most important condition 
reported for botanical cannabis is for severe pain, either alone 
or in combination with other conditions, the proposed 
dispensary registry model needs to monitor the use of 
prescription pain medications over the course of botanical 
cannabis administration. Given the costs to both individuals and 
health systems of opioid abuse, the registry offers a platform 
for the assessment of the extent to which medical cannabis may 
act as a substitute for prescription opioid medications. Factors 
to consider for the individual patient would be (i) prior and 
current opioid use; (ii) attitudes to medications; (iii) risk 
assessment of potential for medication abuse; and (iv) ongoing 
reporting of medication abuse. The Prometheus registry can 
capture these elements for patients reporting severe pain as a 
condition. The proposed validated instruments for registry are 
the short form 14-item Pain Medication Attitude Questionnaire 
(PMAQ-14) and for opioid risk assessment the Brief Risk 
Questionnaire (BRQ) 8  9  .  
 
It is important to note that there is limited evidence for the 
association between prescription opioid use and botanical 
cannabis. A recent review suggests that implementing medical 
marijuana policies at the state level could reduce opioid 
associated mortality, improve pain management and 
significantly reduce health care costs 10. Even so, with the 
limited evidence base for opioid sparing or substitution for 
opioids, care has to be taken that evidence to support claims is 
relevant to a US medical marijuana dispensing environment. As 
a case in point a recent Australian longitudinal large scale 4-year 
study examines the extent to which botanic cannabis is opioid-
sparing and the impact of cannabis where opioids are also used 
on non-cancer chronic pain outcomes 11. The study, however, 
utilizes responses for subjects using illicit botanical cannabis. 
The fact that the study found that there is no evidence for 
opioid sparing or pain effects is irrelevant to the US where 
dispensaries offer the prospect of a structured approach to 
cannabis use.  
 
Cannabis Administration Options 
Any evaluation of the clinical benefits (and risks or adverse 
events) of cannabis must take account of the delivery method. 
This can have a critical impact on how the formulation is 
metabolized and consequent adjustments to the dosing and 
possible switching to alternative delivery methods. There are 
three methods of delivery: inhalation, oral and topical. 
Inhalation, which is the most popular, can be through either 
smoking or vaporization, with some evidence that the latter 
offers less risk and is preferred medically. For smokers there are 
a range of devices: hand pipes, water pipes, rolling papers, and 
hookahs (which would typically combine with tobacco).  The 
advantage of the vaporizer, with a range of models to choose 
from, is that it steadily heats the cannabis to a temperature high 
enough to release the cannabinoids, but not at a high enough 
temperature to release other potentially harmful toxins. Many 
vaporizers take cannabis concentrates (oil or wax) to be added 
manually or in a cartridge form. 
 
Oral formulations of cannabis include tinctures, ingestible oils, 
and infused food/drinks. While ingestible oils and food/drink are 
absorbed through the digestive tract, tinctures are an oral topical 
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formulation that is immediately absorbed into the bloodstream. 
Finally, topical cannabis, a thick oil that has been decarboxylated to 
activate cannabinoids, is applied as a cream. Absorbed through the 
skin it does not provide a ‘high’ and can address localized soreness 
or muscle aches. 
 
Cannabis Dosing and Titration 
If we consider the role of psychoactive THC (tetrahydrocannabinol) 
and CBD (cannabidol), the most common cannabis products, their 
administration can be classified as: (i) Type 1: THC dominant 
psychoactive varietals with a high THC/low CBD ratio; (ii) Type 2: 
mixed THC/CBD mildly psychoactive cultivars; and (iii) Type 3: CDB 
dominant varietals with a minimal psychoactive effect due to a low 
THC/high CBD ratio. There are also rare cannabis cultivars that 
prominently express a so-called minor cannabinoid (like CBG 
[cannabigerol] or THCV [tetrahydrocannabivarin]).  
 
The focus, in administration and dosing is on Type 1 in recreational 
marijuana retail outlets and Type 3 (and a lesser extent Type 2) in 
medical marijuana dispensaries. Even so, with the range of Type 3 
and Type 2 THC/CBD combinations possible, there is little guidance 
either from the clinical literature or from observational studies as to 
the appropriate dosing of botanical cannabis to achieve a 
therapeutic effect. A situation which MacCallum and Russo, in a 
recent of review of cannabis pharmacology and therapeutics, 
describe as untenable 12. The authors develop a number of 
recommendations for cannabis use. They  point to the importance 
of dose initiation at modest levels with titration of THC over as much 
as two weeks with the daily dose equivalence of THC limited to 
30mg, preferably in conjunction with CBD to avoid adverse events, 
including psychoactive sequelae and development of tolerance. 
CBD may require higher doses as it is less potent than THC. At the 
same time Type 3 micro-dosing with THC (e.g., 1 mg/day) may have 
a low psychoactive yet beneficial therapeutic effect with minimal 
adverse events that are typically found with THC. The authors point 
also to the need to assess drug-drug interactions, maintaining 
standards of care and monitoring patients. This last point is of 
particular importance in registry development: patients should be 
tracked over the course of therapy with careful attention given to 
the method of administration, changes in administration form and 
dosing from cannabis initiation through titration to achieve a 
therapeutic effect.  
 
Detailing the association between dosing, administration and 
therapeutic response is critical as evidence would suggest that 
there is considerable variation in response to similar dosing 
regimens as well as the experience of adverse events. After all, if a 
dispensary is to be considered as more than an outlet for cannabis 
sales, it needs to demonstrate that it is focused on optimizing 
dosing and the appropriate form of cannabis administration for the 
individual patient. There is no single THC/CBD ratio or dosage that 
is optimal for all patients. Indeed, the potential combinations, 
together with recommendations for titrating and monitoring across 
the various administrative forms of cannabis products makes a 
strong case for cannabis therapy as personalized medicine. This has 
the potential to place a premium on dispensaries to maintain 
dosing and administration records.  
 
Provider Interaction 
A common requirement by state governments is for annual re-
certification by a provider for continued cannabis utilization. In 
a previous commentary, as noted above, the argument was 
made that re-certification should be dependent on monitoring 
and reporting cannabis dosing, administration and response. 
Once a dispensary registry is in place, this allows for an ongoing 
interaction with providers. If the provider or caregiver has to re-
certify a patient then a response report from the dispensary 
provides an audited basis to justify re-certification.  
 
It is worth emphasizing the role of the provider. The dispensary 
facilitates access to cannabis and mediates response. It is the 
provider who evaluates (or who should evaluate) the 
contribution of cannabis to therapy targets - whether as 
prescription or as a botanical formulation. If there is no 
indication, in the judgement of the provider, of a therapeutic 
benefit then one option is to deny recertification, leaving it up 
to the individual to switch to recreational marijuana.  
 
The registry is designed to generate automatically reports at 
each dispensary visit with the patient provided with a summary 
response report over baseline or their index visit, and with a 
copy sent to the provider. The added benefit of regular 
reporting to providers is that they may become better 
acquainted with the place of cannabis in therapy and the 
potential risk/benefit profiles for patients. This may go some 
way to offset the lack of preparation by medical schools for 
cannabis prescribing with few physicians feeling they are 
qualified to counsel patients about dosage, CBD:THC ratios, 
different modes of administration and potential side effects 13. 
 
Cannabis Claims 
Reporting outcomes on a regular basis does not, of course, 
imply any causal relationship between cannabis and 
therapeutic response. Regardless of how strong an association 
is noted or claimed, a rigorous statistical assessment would be 
required to support potential claims for the independent effect 
of cannabis. One of the objectives of a registry is to build a 
database that would allow this to be undertaken. This is why a 
range of data points and potential confounding factors are 
captured from both registry staff and patients over the course 
of treatment. While observational study data are often 
considered of a lower quality compared to classical RCTs, well 
conducted phase 4 observational study assessments based on 
a cannabis registry can not only complement but allow for the 
evaluation and replication of RCT based cannabis claims in 
treatment practice.  
 
Registry Software Environment 
The Prometheus registry utilizes the proprietary REX Registry 
platform developed by Prometheus Research. The REX Registry 
platform is based on open source technologies and standards, 
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which can be tailored to address the specific needs of a 
dispensary or other health system environment  without 
locking the user into a proprietary dead end. Most importantly 
for the development of a botantical cannabis evidence base, 
RexRegistry facilitates healthcare research by quickly and 
efficiently responding to new types of data, new methods of 
acquiring data, and new ways of transforming and reusing 
existing data. The result is a unique combination of tools and 
processes that ensure your high-quality data is able to meet 
today’s regulatory requirements and still answer tomorrow’s 
unknown research questions. 
 
Registry Data Assembly 
The registry structure requires inputs from both the dispensary 
staff and the patient over the course of treatment.  As well, the 
data inputs need to distinguish patients reporting with a single 
condition from those with multiple conditions in order to assess 
cannabis response. The proposed data entry on-line ‘screens’ 
are: 
 
(i) initial data input by registry staff;  
(ii) subsequent or follow-up visit data entry by 
dispensary staff;  
(iii) initial data entry by patient for single 
condition/symptom reported;  
(iv) subsequent or follow-up data entry by patient for 
single condition/symptom reported; 
(v) initial data entry by patient for two 
conditions/symptoms reported;  
(vi) subsequent or follow-up data entry by patient for 
two conditions/symptoms reported. 
 
In order to limit the operational complexity of data entry to the 
registry where multiple conditions may be reported by the 
patient, it restricts monitoring to a maximum of two conditions. 
In addition, as well over 90% of patients will report one or more 
of four conditions (severe pain, severe nausea or vomiting, 
severe muscle spasms or cramps and seizures), the number of 
possible specific ‘high prevalence’ target groups would be: 
 
• Severe pain 
• Persistent muscle spasms 
• Severe nausea 
• Seizures 
• Severe pain + persistent muscle spasms 
• Severe pain + severe nausea 
• Severe pain + seizures 
• Persistent muscle spasms + severe nausea 
• Persistent muscle spasms + seizures 
• Severe nausea + seizures 
• General (none of the above) 
 
If a patient reports more than one condition then a composite 
questionnaire is automatically created with drop-in questions. 
Given the prevalence of chronic pain, if composite conditions 
include severe pain then this is the ‘primary’ questionnaire with 
the co-morbid condition questions (for persistent muscle 
spasms, severe nausea and/or seizures) ‘dropped in’ to the 
severe pain questionnaire. Otherwise, patients complete the 
‘general’ questionnaire which is not condition specific even 
though the conditions are reported as part of the dispensary 
data entry. 
 
As noted above, the registry adopts a modular or functional 
form. The registry could be configured in the first instance only 
for severe pain. This could be enhanced by then integrating 
responses for patients also reporting one or more of severe 
nausea, persistent muscle spasms or seizures. As familiarity 
with the registry grows, modules for patients reporting severe 
nausea, persistent muscle spasms and seizures could be added 
with further conditions captured in customizing the registry 
structure. 
 
Initial Data Entry by Dispensary Staff 
Initial data entry by registry clinical staff and the patient 
establishes the baseline for evaluating overall response to 
dispensed cannabis formulations and delivery mode. The data 
elements proposed are:  
 
• Patient ID and certification for medical marijuana 
• Provider and (if appropriate) caregiver contact 
• Diagnosis for certification 
• Condition(s) reported (e.g., severe pain, severe 
nausea, persistent muscle spasms) 
• Medications: prescription opioid utilization 
• Medications: other prescription medications 
• Attitudes and risk assessment for medication 
utilization 
• DNA evaluation (if appropriate) 
• Cannabis formulation/dosing 
• Previous cannabis use 
• Alcohol use 
• Tobacco use 
 
Initial Patient Data Entry: General 
The initial data entry report completed online by the patient 
will include basic demographic and work status questions: 
 
• Gender 
• Age 
• Marital status 
• Race/Hispanic origin 
• Education 
• Employment status 
• Main reason for not working  
• Present health (Excellent, very good, good, fair, poor) 
• Previous health (12 months ago: better, worst, about 
the same, don’t know) 
 
Common to all reports completed on-line by the patient are 
proposed responses to four validated PROs for: (i) fatigue; (ii) 
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anxiety; (iii) depression and (iv) sleep experience. The proposed 
PROs, which are all in the public domain and widely utilized are: 
 
• Fatigue: Fatigue Severity Scale 14 15 
• Anxiety: GAD-7 Anxiety Scale 16 
• Depression: PHQ-9  
• Sleep Experience: RAND Sleep Questionnaire 17 
 
Initial Patient Data Entry: Severe Pain 
Non-cancer severe pain, as noted above, is the single most 
frequently reported condition from medical dispensaries. This 
means that pain assessment needs careful attention as failure 
to report pain status over the course of their cannabis exposure 
can be a major barrier to physician acceptance of cannabis as a 
potential mainstay of therapy. This applies, in particular, when 
recommending cannabis as a treatment option if it is combined 
with other medications (e.g., opioids, NSAIDS) or is ancillary to 
surgical interventions (e.g., spinal cord stimulation).  
 
Patients reporting severe pain are asked to detail their 
experience with severe pain over their exposure to cannabis at 
two levels: (i) overall pain experience and (ii) pain experience 
by body location. Overall patients, at the initial visit, are asked 
to report their present and recent experience with pain, 
together with their experience with pain over the past six 
months (worst pain, average pain intensity, impact on 
activities). Together with PRO scores, this allows an assessment 
of the likelihood of continuing chronic pain to be calibrated 18 
19.  
 
It is important to be as precise as possible regarding the 
intensity and functional status of pain experienced by the 
patient to establish a baseline for evaluating the association 
between choice of cannabis formulation and dosing and any 
clinically significant change in pain intensity and functional 
status. The following pain locations are detailed in the registry 
data collection protocols with validated functional status PROs 
and self-reported pain intensity for each (with multiple pain 
locations reported if appropriate): 
 
• Head pain: Migraine Disability Assessment (MIDAS) 
questionnaire 20 
• Face, mouth or jaw pain: Manchester Orofacial Pain 
Disability Scale 21  
• Neck pain: Copenhagen Neck Functional Disability 
Scale 22 
• Shoulder or upper arm pain: QuickDASH 23 
• Elbow, wrist or hand pain: QuickDASH 
• Mid-back (thoracic) pain: Roland Morris Scale 24 25 
• Low-back (lumbar) pain: Roland Morris Scale 
• Hip pain: Lower Extremity Functional Scale 26 
• Lower abdominal pain: Male /Female NIH-C PSID 
Abdominal Pain Questionnaire 27 
• Knee or leg pain: Lower Extremity Functional Scale 28 
• Foot or Heel Pain: Lower Extremity Functional Scale 
Patients are also assessed for their  likelihood of experiencing 
neuropathic pain. The proposed PRO instrument  is the ID-Pain 
instrument 29 . 
 
Initial Patient Data Entry: Persistent Muscle Spasms 
A muscle spasm or cramp is an involuntary contraction of one 
or more muscles occurring at rest. These are, as noted above, 
typically the second most frequently reported condition by 
dispensaries and may occur in association with severe pain. The 
following measures are proposed to capture experience with 
muscle spasms at baseline and over the course of cannabis 
therapy:  
 
• Worst severity of persistent muscle  spasms or 
cramps over last 4 weeks (10 point Likert scale) 
• Occurrence of persistent muscle spasms or cramps in 
last 4 weeks (e.g., only at night, only when exercising) 
• Frequency of persistent muscle spasms or cramps 
(e.g., all the time, about once a week) 
• Usual severity of persistent muscle spasms or cramps 
in past 4 weeks (10 point Likert scale) 
• Impact on sleep (frequency of interference) 
 
Although any change noted should not necessarily be 
attributable to cannabis the registry would capture current 
status at each dispensary visit and potentially generate reports 
for the patient and provider detailing change over baseline. 
These reports would be generated for all subsequent visits. 
 
Initial Patient Data Entry: Severe Nausea 
In tracking the association between severe nausea and/or 
vomiting, where the former refers to feeling sick to one’s 
stomach and vomiting means actually throwing up, it is useful 
to distinguish between patients receiving chemotherapy from 
those whose nausea and/or vomiting may be associated with 
other illnesses and conditions including indigestion, the 
presence of an ulcer and the side effects of medications.  
 
For those patients reporting that they are on chemotherapy 
the key questions to ask for the patient’s last chemotherapy 
treatment: 
 
• When was the nausea/vomiting experienced (before, 
during or after chemotherapy) 
• Duration of nausea/vomiting experience (hours, days) 
• Worst nausea/vomiting experience (mild to 
intolerable) 
 
Where nausea/vomiting are not reported as related to 
chemotherapy treatment the key questions to ask are: 
 
• Nausea/vomiting frequency in last visit (or in last 4 
weeks for initial visit) (e.g., daily, once  a week) 
• Worst nausea/vomiting experience since last visit (or 
in last 4 weeks for initial visit) (e.g., very mild, severe) 
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Initial Patient Data Entry: Seizures 
Seizures related to epilepsy present an interesting challenge for 
dispensaries. There is a significant evidence base to suggest 
positive benefits in the treatment of refractory epilepsy, 
notably the evidence base for cannabis in Lennox-Gastaut and 
Dravel syndromes with consequent marketing approval by the 
FDA for Marinol/Syndros (dronabinol), Cesamet (nabilone) and 
Epidiolex (cannabidiol)   30.  Rather than attempting to 
document the range of seizure types and their frequency by 
either a patient diary or recall, the approach proposed here is 
to utilize the QOLIE 31 Quality of Life in Epilepsy (RAND Version 
1.0) questionnaire. The QOLIE-31 is the short-form version of 
the original long-form QOLIE-89 and has been used extensively 
in epilepsy and related seizure conditions.  While this does not 
exclude asking patients to detail all-type seizure frequency 
together with, adverse events and withdrawals over the course 
of their exposure to cannabis, the QOLIE-31 captures a number 
of aspects of seizure experience that may impact the 
contribution of reduced seizure frequency to quality of life. 
 
The QOLIE-31 generates both an overall weighted score as 
well as 7 multi-item sub-scales. The sub-scales are: 
 
• Seizure worry 
• Overall quality of life 
• Emotional  well-being 
• Energy/fatigue 
• Cognitive  
• Medication effects 
• Social function 
The minimum clinically important change in the overall QOLIE-
31 score is 11.8 points  31.  
Subsequent Visit Data Entry by Dispensary Staff and Patients 
The focus of subsequent reports by dispensary staff and 
patients is to record change over baseline in the measures 
selected to monitor cannabis response. Change can be reported 
but it has to be interpreted appropriately. This is the role of the 
dispensary registry which can report on change over baseline 
for individual patients as well as case-series change over 
baseline for target groups defined by combinations, for 
example, of conditions reported and change in those conditions 
by cannabis formulation and dosing regimen.  
 
Proposed subsequent data entry by patients is designed to 
record response to therapy and to report change over baseline. 
At each subsequent dispensary visit patients complete an 
online questionnaire (ideally online before the visit) to capture 
current status and their experience with cannabis over the 
period since their last visit. Questions on socio-demographic 
status are dropped with the exception of a question on current 
employment status. The general health question is retained 
together with all other questions from the initial visit 
questionnaire. At the same time it is proposed, as noted above, 
that patients at each successive visit complete the (PGIC) scale.  
 
Proposed subsequent data entry by dispensary staff focuses on 
cannabis utilization. At each visit the staff would record 
cannabis dosing and formulation, together with adverse events. 
This allows a profile of cannabis use to be developed, tracking 
patients over the course of their purchases of marijuana from 
the dispensary. This is a critical element as it allows change in 
outcomes reported to be linked to factors such as dosing 
composition and strength as well as to the delivery form.  
 
At the same time patients are asked to report current 
prescription medications, to include continued prescription 
opioid use and whether they have experience adverse events 
since their last dispensary visit. As the patient visit report will 
be available to the dispensary clinical staff as a summary report 
this allows the staff to evaluate response to therapy and to 
make recommendations for possible changes in cannabis 
regimen. 
 
Reporting Response to Therapy  
The advantage of a registry is that the cannabis data base 
provides a structured framework for report generation. Reports 
can be created within the registry for individual patients as case 
studies of therapy response as well as reports for target patient 
groups to support overall dispensary management and 
reporting to outside agencies.  
 
At each dispensary visit, it is proposed that patients receive a 
report on their current status by condition(s) reported over 
baseline. This report would be reviewed with the clinical staff 
the dispensary with, if required, recommended changes to 
either the dosing regimen and/or delivery option. This review 
of response to therapy would include both assessed clinical 
benefits from condition specific PRO instruments but also the 
core PROs for fatigue, anxiety, depression, sleep together with 
the PGIC for the patients’ own assessment of their cannabis 
experience.  
 
If agreed with the patient, a copy of this visit report would be 
sent to the provider or caregiver together with recommended 
regimen changes. With annual re-certification of patients for 
medical marijuana, regular reports to providers on dosing, 
administration and response to therapy with validated 
instruments specific to the condition(s) being treated provide a 
potentially robust base for therapy decisions. The provider is 
then in a position to recommend or deny recertification.   
 
Understandably, dispensary staff and management might 
consider these reporting requirements to be onerous. In fact, 
they would be little different from reports provided to primary 
care physicians by specialists. The registry system would 
automatically generate these reports with the option of further 
notation by dispensary clinical staff. Given the requirements for 
recertification of patients for access to a dispensary, there 
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would appear to be little option for the dispensary to monitor 
patients, reporting on response to therapy using validated 
instruments and linking the response to cannabis dosing, 
titration and administration. 
 
In some cases, state agencies may require a formal audit trail 
capability. Just as an electronic medical record provides an 
audit trail, the Prometheus registry would provide a framework 
that can be used by dispensary management in cases of dispute 
resolution with third parties, demonstrating a commitment to 
their duty of care to the patient.  
 
From a dispensary management perspective, the Prometheus 
registry data allows a range of reports to be considered. These 
could focus on the response to therapy by target patient groups 
defined by condition and cannabis dosing/formulation and 
delivery. Reports can also be tailored to the requests from third 
parties, encompassing both summary data in the form of 
reports or access to de-identified unit patient records. Third 
parties, as an example, could be offered access to selected unit 
records to generate tables and undertake multivariate 
evaluations of cannabis response.  
 
Conclusions 
A major barrier to physician acceptance and advocacy of 
cannabis as a therapy option is the limited evidence base for 
cannabis. A situation which is made all the more opaque by the 
absence of commitments both by state governments in 
legislating standards for dispensary licensing and by individual 
dispensaries to report their experience with the various 
formulations and dosing options offered by dispensary retail 
staff. Unless the limited claims for cannabis use by formulation 
and dosing from well conducted RCTs can be complemented by 
similarly well conducted assessments of the impact of cannabis 
on severe pain, muscle spasms, nausea and seizures (among 
other conditions) from registries supporting observational 
studies, providers are unlikely to recognize cannabis as a 
therapy option. Indeed, legislators are likely to also raise 
questions as to the role of dispensaries. The perception may be 
that they are simply a gateway for cannabis use with only 
perfunctory assessments of cannabis need and with little if any 
attention, beyond possible adverse event reporting, to a 
rigorous reporting of outcomes associated with cannabis use. 
With limited licenses typically designated by state 
governments, investors may look at dispensaries as just 
another variant of taxi medallions. An investment that promises 
a significant rate of return as the value of the license increases, 
particularly as states take the further step of legislating 
recreational marijuana without necessarily increasing the 
number of dispensary licenses.   
 
With the move towards recreational marijuana licensing, 
investors in dispensaries, unless they can put forward claims for 
benefits in monitoring patients and reporting outcomes to 
providers, may well be faced with patients self-medicating 
through recreational marijuana. Rather than seeking 
certification through state health departments, patients may 
see recreational marijuana as a more accessible and low cost 
option. A major benefit from the Prometheus registry for a 
medical marijuana dispensary as opposed to  retail recreational, 
is that reports can be provided both to the patient and provider 
recording any changes in condition status and whether the 
change is considered clinically significant. In the absence of a 
legislative mandate, the responsibility rests with dispensaries 
to justify their place in therapy.  
 
Will there be an acceptance by medical marijuana dispensaries 
to adopt a registry model? If the focus by investors and owners 
is on cannabis sales with an expected increase in the price of 
licenses then this is unlikely. Against this is the acceptance, to 
include investors and owners, that they have a duty of care for 
patients presenting with conditions for which cannabis is an 
option. Such a commitment would recognize the importance of 
evidence based claims for outcomes potential, to recognize 
they have a place in the continuum of care and that feedback 
with providers to justify cannabis is not only clinically desirable 
but may encourage greater cannabis use. If those holding 
licenses that are subject competitive renewal and those 
competing for new licenses recognize this responsibility, then it 
may put them in a preferred position with competitive bidding. 
 
Conflict(s) of Interest: None reported. PCL developed the 
structure and content of the registry. Prometheus Research 
provided the registry software support and delivery.  
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